Outlook for 2015: Antitrust Litigation in the Pharma Industry—More Than Just Actavis Progeny

In 2014 there were a number of significant antitrust developments related to litigation in the pharmaceutical industry. These involved not only pharmaceutical patent litigation settlements (so-called "reverse payment" agreements), but also conduct related to product reformulations and Risk Evaluation and Mitigation Strategies activity.

Read More: Outlook for 2015: Antitrust Litigation in the Pharma Industry—More Than Just Actavis Progeny


Download PDF Share Back To Listing
Loading data